

HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Report – September 15, 2018
Data through : September 15, 2018
Table 3 – Retention¹ by Visit and Site²

	Overall	Gaborone	St.Mary's Clinic	Parirenyatwa	Zengeza	Soweto	Ward 21
N Enrolled	190	13	29	25	21	51	51
Step 1							
Week 2	175/181 (96.7%)	11/12 (91.7%)	28/29 (96.6%)	22/25 (88.0%)	20/20 (100.0%)	46/47 (97.9%)	48/48 (100.0%)
Week 4	168/176 (95.5%)	11/12 (91.7%)	29/29 (100.0%)	21/25 (84.0%)	20/20 (100.0%)	42/44 (95.5%)	45/46 (97.8%)
Step 2							
Week 5 (Injection #1)	165/166 (99.4%)	10/10 (100.0%)	29/29 (100.0%)	23/23 (100.0%)	19/19 (100.0%)	42/43 (97.7%)	42/42 (100.0%)
Week 6 Safety Visit	153/166 (92.2%)	10/12 (83.3%)	28/29 (96.6%)	19/25 (76.0%)	19/20 (95.0%)	39/40 (97.5%)	38/40 (95.0%)
Week 9 (Injection #2)	141/151 (93.4%)	9/12 (75.0%)	28/29 (96.6%)	22/25 (88.0%)	19/20 (95.0%)	32/33 (97.0%)	31/32 (96.9%)
Week 13 Safety Visit	141/151 (93.4%)	9/12 (75.0%)	28/29 (96.6%)	22/25 (88.0%)	19/20 (95.0%)	32/33 (97.0%)	31/32 (96.9%)
Week 17 (Injection #3)	135/146 (92.5%)	9/11 (81.8%)	27/29 (93.1%)	20/23 (87.0%)	16/18 (88.9%)	32/33 (97.0%)	31/32 (96.9%)
Week 21 Safety Visit	104/115 (90.4%)	4/7 (57.1%)	14/14 (100.0%)	13/16 (81.3%)	12/15 (80.0%)	31/32 (96.9%)	30/31 (96.8%)
Week 25 (Injection #4)	84/90 (93.3%)	3/4 (75.0%)	8/9 (88.9%)	6/7 (85.7%)	12/14 (85.7%)	28/29 (96.6%)	27/27 (100.0%)
Week 33 (Injection #5)	18/20 (90.0%)	1/1 (100.0%)	0/0 (-%)	1/1 (100.0%)	0/0 (-%)	7/8 (87.5%)	9/10 (90.0%)
Week 41 (Injection #6)	2/3 (66.7%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	2/3 (66.7%)	0/0 (-%)
Week 42 Safety Visit	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 49 (Injection #7)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 57 (Injection #8)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 65 (Injection #9)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 73 (Injection #10)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 81 (Injection #11)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 89 (Injection #12)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 97 (Injection #13)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 105 (Injection #14)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 113 (Injection #15)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 121 (Injection #16)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 129 (Injection #17)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 137 (Injection #18)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 145 (Injection #19)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 153 (Injection #20)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 161 (Injection #21)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 169 (Injection #22)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)

¹Percent of evaluated participants who completed each visit. Evaluated participants are those whose visit window has closed as of the cutoff date plus those that completed the visit although the window is not yet closed.
² Only sites with enrolled participants are shown. Inappropriately enrolled participants are excluded. There are currently 0 inappropriately enrolled participants.

**HPTN 084 – A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for
 Pre-Exposure Prophylaxis in HIV-Uninfected Women
 Report – September 15, 2018
 Data through : September 15, 2018
 Table 3 – Retention¹ by Visit and Site²**

	Overall	Gaborone	St.Mary's Clinic	Parirenyatwa	Zengeza	Soweto	Ward 21
Week 177 (Injection #23)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)
Week 185 (Injection #24)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)	0/0 (-%)

¹Percent of evaluated participants who completed each visit. Evaluated participants are those whose visit window has closed as of the cutoff date plus those that completed the visit although the window is not yet closed.
² Only sites with enrolled participants are shown. Inappropriately enrolled participants are excluded. There are currently 0 inappropriately enrolled participants.